Literature DB >> 14715849

Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry.

Wolfgang Högler1, Julie Briody, Bin Moore, Sarah Garnett, Pei Wen Lu, Christopher T Cowell.   

Abstract

Osteoporosis and fractures are features in adults with Turner syndrome (TS). Using dual-energy x-ray absorptiometry, correcting bone mineral content (BMC) for height and lean mass (LTM) avoids misclassification of short children as osteopenic. Total body (TB), lumbar spine (LS), and femoral neck (FN) dual-energy x-ray absorptiometry scans were performed on 83 patients with TS (aged 4-24 yr). A prepubertal subgroup (n = 17) receiving GH was followed for 24 months. Age z-scores for height, TB BMC, LTM, the BMC/LTM ratio, and LS volumetric bone mineral density (vBMD) decreased significantly (P < 0.001) with age in prepubertal subjects (n = 51) but were constant in the combined pubertal and postmenarchal group (n = 32). Osteopenia was found in 14.5% (TB), 15.8% (LS), and 28.4% (FN) of patients. In the longitudinal subgroup, TB BMC z-scores decreased by -0.28 (0.31) in subjects remaining prepubertal (n = 11) but increased by 0.71 (0.56) in subjects entering puberty (n = 6; P = 0.007). The z-scores for height and LTM increased in both groups. Our results show a height-independent prepubertal decrease in bone mass accrual, which ceased with puberty. Optimizing bone mass in TS may require earlier induction of puberty than currently recommended. However, reduced FN volumetric bone mineral density and a dissociation of bone and muscle measures were age independent, suggesting an additional intrinsic bone defect.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715849     DOI: 10.1210/jc.2003-030799

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 2.  Effects of hypogonadism on bone metabolism in female adolescents and young adults.

Authors:  Madhusmita Misra
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

3.  Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Charmian A Quigley; Xiaohai Wan; Sipi Garg; Karen Kowal; Gordon B Cutler; Judith L Ross
Journal:  J Clin Endocrinol Metab       Date:  2014-04-24       Impact factor: 5.958

4.  Artificially low cortical bone mineral density in Turner syndrome is due to the partial volume effect.

Authors:  O Soucek; E Schönau; J Lebl; Z Sumnik
Journal:  Osteoporos Int       Date:  2014-10-07       Impact factor: 4.507

5.  Bone size and density measurements in prepubertal children with Turner syndrome prior to growth hormone therapy.

Authors:  P Pitukcheewanont; N Numbenjapon; D Safani; S Rossmiller; V Gilsanz; G Costin
Journal:  Osteoporos Int       Date:  2010-09-09       Impact factor: 4.507

Review 6.  Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.

Authors:  Shannon D Sullivan; Philip M Sarrel; Lawrence M Nelson
Journal:  Fertil Steril       Date:  2016-12       Impact factor: 7.329

Review 7.  Fracture risk and bone mineral density in Turner syndrome.

Authors:  Vladimir K Bakalov; Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2008-04-15       Impact factor: 6.514

8.  Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial.

Authors:  Emma Jane Gault; Rebecca J Perry; Tim J Cole; Sarah Casey; Wendy F Paterson; Peter C Hindmarsh; Peter Betts; David B Dunger; Malcolm D C Donaldson
Journal:  BMJ       Date:  2011-04-14

9.  Recombinant human growth hormone in the treatment of Turner syndrome.

Authors:  Bessie E Spiliotis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 10.  Bone Fragility in Turner Syndrome: Mechanisms and Prevention Strategies.

Authors:  Maria Felicia Faienza; Annamaria Ventura; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-04-26       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.